Assembly Biosciences 将在即将举行的 AASLD The Liver Meeting®

StephenW

Assembly Biosciences 将在即将举行的 AASLD The Liver Meeting® 上以四份海报展示数据

美国东部时间 2022 年 10 月 24 日 08:00 |资料来源：Assembly Biosciences, Inc.

四个海报展示，包括两个最新的，突出病毒学组合的广度和承诺

显示下一代核心抑制剂 ABI-4334 对乙型肝炎病毒的临床前活性的数据支持计划在年底前进入临床研究

加利福尼亚州南旧金山，2022 年 10 月 24 日 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) 是一家临床阶段的生物技术公司，开发针对乙型肝炎病毒 (HBV) 和其他病毒的创新研究性疗法疾病，今天宣布，其病毒学组合的临床和临床前数据将在即将于 11 月举行的美国肝病研究协会 (AASLD) 肝脏会议® 上以四个海报展示的形式展示，其中包括两个较晚的突破性展示。 2022 年 4 月 8 日至 8 日，华盛顿特区。

演示文稿将包括支持公司下一代核心抑制剂候选药物 ABI-4334 (4334) 进入治疗乙型肝炎病毒 (HBV) 临床开发的临床前数据，预计将于 H2 开始进行 1a 期试验2022 年，还将展示 Assembly Bio 公司针对 HBV 和丁型肝炎病毒 (HDV) 的新型小分子病毒进入抑制剂的临床前特征数据。此外，两个被接受为最新摘要的海报展示将侧重于 Assembly Bio 的干扰素-α 受体（ IFNAR ）激动剂研究计划和正在进行的 2 期研究，该研究评估第一代核心抑制剂 vebicorvir 与 Arbutus Biopharma 的 AB-729 在 HBV 中的组合。

“我们期待在 AASLD 的肝脏会议上展示数据，这些数据展示了我们管道的前景、我们的科学实力以及我们扩大研究工作的广度，”Assembly Bio 首席科学官 William Delaney 博士说。 “值得注意的是，我们将强调探索我们高效的下一代核心抑制剂 4334 对 cccDNA（HBV 病毒库）形成的活性的临床前数据。我们还将首次展示我们今年早些时候推出的口服病毒进入抑制剂研究计划的临床前数据，该计划以我们的核心抑制剂组合为基础，具有针对 HBV 的互补机制，同时还将我们的研究重点扩展到 HDV。”

海报展示详情如下；关于另外两张最新海报的详细介绍将在会议临近时提供：

    海报展示 #1119：ABI-4334，一种新型乙型肝炎病毒核心抑制剂，通过多种途径加速衣壳组装并抑制 cccDNA 形成
    第一作者：Nuruddin Unchwaniwala，博士，Assembly Bio
    会议：海报
    日期和时间：2022 年 11 月 4 日，星期五，下午 12:00外星人
    海报展示#1132：一类新型高效小分子乙型和丁型肝炎病毒进入抑制剂的临床前表征
    第一作者：Heidi Contreras，博士，Assembly Bio
    会议：海报
    日期和时间：2022 年 11 月 4 日，星期五，下午 12:00外星人

AASLD 演示文稿和海报
演示文稿和海报预计将在演示文稿的 72 小时内通过 The Liver Meeting Digital Experience™ 在线提供给会议注册者，网址为 https://www.aasld.org/the-liver-meeting/digital-experience。完整的海报将在大会网站 www.assemblybio.com 的“投资者”部分的“活动和演示”页面上在线提供。

StephenW

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

October 24, 2022 08:00 ET | Source: Assembly Biosciences, Inc.

Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio

Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned advancement into clinical studies before year end

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that clinical and preclinical data from its virology portfolio will be featured in four poster presentations, including two late breaker presentations, at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 4-8, 2022, in Washington, DC.

The presentations will include preclinical data supporting the advancement of the company’s next-generation core inhibitor candidate, ABI-4334 (4334), into clinical development for the treatment of hepatitis B virus (HBV), with a Phase 1a trial expected to start in H2 2022. Data highlighting the preclinical characterization of Assembly Bio’s novel small molecule viral entry inhibitor for HBV and hepatitis delta virus (HDV) will also be presented. Additionally, two poster presentations accepted as late-breaking abstracts will focus on Assembly Bio’s interferon-α receptor (IFNAR) agonist research program and the ongoing Phase 2 study evaluating first-generation core inhibitor vebicorvir in combination with Arbutus Biopharma’s AB-729 in HBV.

“We look forward to presenting data at AASLD’s The Liver Meeting that demonstrate the promise of our pipeline, strength of our science and breadth of our expanded research efforts,” said William Delaney, PhD, chief scientific officer of Assembly Bio. “Notably, we will highlight preclinical data exploring the activity of our highly potent next-generation core inhibitor 4334 against the formation of cccDNA, the HBV viral reservoir. We will also present for the first time preclinical data from our oral viral entry inhibitor research program introduced earlier this year, which builds upon our core inhibitor portfolio with a complementary mechanism against HBV while also extending our research focus to HDV.”

Details of the poster presentations are as follows; presentation details on the two additional late-breaking posters will be available closer to the meeting:

    Poster Presentation #1119: ABI-4334, a novel hepatitis B virus core inhibitor, accelerates capsid assembly and inhibits cccDNA formation via multiple pathways
    First Author: Nuruddin Unchwaniwala, PhD, Assembly Bio
    Session: Posters
    Date and Time: Friday, November 4, 2022, 12:00 p.m. ET
    Poster Presentation #1132: Preclinical characterization of a novel class of highly potent small molecule hepatitis B and D virus entry inhibitors
    First Author: Heidi Contreras, PhD, Assembly Bio
    Session: Posters
    Date and Time: Friday, November 4, 2022, 12:00 p.m. ET

AASLD Presentations and Posters
Presentations and posters are expected to be made available online to conference registrants through The Liver Meeting Digital Experience™ at https://www.aasld.org/the-liver-meeting/digital-experience within 72 hours of presentation. The full posters will be available online at the “Events & Presentations” page in the “Investors” section of Assembly's website at www.assemblybio.com.